LIR Life Sciences Corp

LIR Life Sciences Corp. is a mineral exploration company, which engages in the identification, acquisition, evaluation, and exploration of mineral properties. The firm is engaged in developing therapies across multiple treatment areas, with a focus on obesity and metabolic disorders. The company develops glucagon-like peptide-1 (GLP-1) based therapies for patients. The company has access to a drug delivery system and plans to utilize technology to enable the needle-free administration of complex large-molecule biologics which provides a potential alternative to injectable treatments across a wide variety of treatments and diseases. The firm develops LIR001 Dual-Action Therapy (LIR001). LIR001 combines GLP-1 receptor agonists with other drugs to enhance obesity treatment by targeting both metabolic and behavioral factors. GLP-1 receptor agonists, such as liraglutide and semaglutide, regulate blood sugar, promote insulin release, and slow gastric emptying, leading to reduced appetite and improved insulin sensitivity.